摘要
目的研究氧化苦参碱(oxymatrine,OMT)对人脐静脉内皮细胞(human umbilical vein endothelial cells,HUVEC)体外缺血再灌注(ischemia reperfusion,I/R)损伤的保护作用及其分子机制。方法将HUVEC分为对照组、I/R组和OMT 0. 5、1、2μg/ml组,对照组为正常培养细胞,I/R组和OMT 0. 5、1、2μg/ml组均制备I/R损伤模型,OMT0. 5、1、2μg/ml组分别给予OMT 0. 5、1、2μg/ml处理。检测5组细胞存活率、乳酸脱氢酶(LDH)含量、细胞凋亡情况及Bcl-2、Bax、Caspase-3蛋白表达水平。结果与I/R组比较,OMT 0. 5、1、2μg/ml组HUVEC存活率升高,培养液中LDH含量降低,细胞凋亡减少,Bcl-2/Bax逐渐上调,Caspase-3蛋白表达下调,且呈剂量依赖性(P <0. 05,P <0. 01)。结论 OMT对HUVEC体外I/R损伤有保护作用,其机制可能与减少细胞凋亡有关。
Objective To study protective effect of Oxymatrine (OMT) on human umbilical vein endothelial cells (HUVEC) ischemia-reperfusion (I/R) injury in vitro and its molecular mechanism. Methods HUVEC were divided into control group, I/R group, 0.5, 1 and 2μg /ml OMT groups. Control group was normal cultured cells. I/R group, 0.5, 1 and 2μg/ml OMT groups were prepared I/R injury models. The 0.5, 1 and 2μg/ml OMT groups were treated with 0.5, 1 and 2μg/ml OMT respectively. Cell survival rate, lactate dehydrogenase (LDH) contents, conditions of cell apoptosis and expressions of Bcl-2, Bax and Caspase-3 proteins were detected among 5 groups. Results Compared with those in I/R group, in 0.5, 1 and 2μg /ml OMT groups, survival rates of HUVEC were increased;LDH contents in culture medium were decreased;numbers of cell apoptosis were decreased;values of Bcl-2/Bax were increased gradually;expressions of Caspase-3 proteins were decreased in a dose-dependent manner ( P <0.05, P <0.01). Conclusion Oxymatrine has protective effects on HUVEC ischemia-reperfusion injury in vitro, and its mechanism may be related to reduction of apoptosis.
作者
颜治云
张青
张梅
YAN Zhi-Yun;ZHANG Qing;ZHANG Mei(Logistics College of Chinese People's Armed Police Forces, Tianjin 300309, China;73131 Military Health Company, Longhai, Fujian 363113, China;Department of Digestive Tract Diseases,Department of Cardiology,Specialized Medical Center of Chinese People's Armed Police Forces, Tianjin 300162, China;Department of Cardiology, 3Specialized Medical Center of Chinese People's Armed Police Forces, Tianjin 300162, China)
出处
《解放军医药杂志》
CAS
2019年第4期22-26,共5页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
天津市自然科学基金重点项目(16JCZDJC31900)